Literature DB >> 22274690

Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.

David M Hyman, David R Spriggs.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22274690      PMCID： PMC3642768          DOI： 10.1001/jama.2012.24

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  22 in total

1.  Genetic/familial high-risk assessment: breast and ovarian.

Authors:  Mary B Daly; Jennifer E Axilbund; Saundra Buys; Beth Crawford; Carolyn D Farrell; Susan Friedman; Judy E Garber; Salil Goorha; Stephen B Gruber; Heather Hampel; Virginia Kaklamani; Wendy Kohlmann; Allison Kurian; Jennifer Litton; P Kelly Marcom; Robert Nussbaum; Kenneth Offit; Tuya Pal; Boris Pasche; Robert Pilarski; Gwen Reiser; Kristen Mahoney Shannon; Jeffrey R Smith; Elizabeth Swisher; Jeffrey N Weitzel
Journal:  J Natl Compr Canc Netw       Date:  2010-05       Impact factor: 11.908

2.  Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Authors:  Noah D Kauff
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

3.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

4.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.

Authors:  Tuya Pal; Jenny Permuth-Wey; Judith A Betts; Jeffrey P Krischer; James Fiorica; Hector Arango; James LaPolla; Mitchell Hoffman; Martin A Martino; Katie Wakeley; George Wilbanks; Santo Nicosia; Alan Cantor; Rebecca Sutphen
Journal:  Cancer       Date:  2005-12-15       Impact factor: 6.860

5.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Authors:  M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

6.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.

Authors:  Angela Chetrit; Galit Hirsh-Yechezkel; Yehuda Ben-David; Flora Lubin; Eitan Friedman; Siegal Sadetzki
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

7.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

8.  Meta-analysis of BRCA1 and BRCA2 penetrance.

Authors:  Sining Chen; Giovanni Parmigiani
Journal:  J Clin Oncol       Date:  2007-04-10       Impact factor: 44.544

9.  Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

Authors:  Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark E Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck
Journal:  J Clin Oncol       Date:  2008-02-11       Impact factor: 44.544

10.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Authors:  Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544
View more
  3 in total

1.  Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.

Authors:  Qian Zhong; Hong-Ling Peng; Xia Zhao; Lin Zhang; Wei-Ting Hwang
Journal:  Clin Cancer Res       Date:  2014-10-27       Impact factor: 12.531

2.  Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry.

Authors:  J S Ferris; M B Daly; S S Buys; J M Genkinger; Y Liao; M B Terry
Journal:  Br J Cancer       Date:  2014-01-07       Impact factor: 7.640

3.  BRCA1/2 variants and copy number alterations status in non familial triple negative breast cancer and high grade serous ovarian cancer.

Authors:  Fatima Zahra El Ansari; Farah Jouali; Rim Fekkak; Joaira Bakkach; Naima Ghailani Nourouti; Amina Barakat; Mohcine Bennani Mechita; Jamal Fekkak
Journal:  Hered Cancer Clin Pract       Date:  2022-08-19       Impact factor: 2.164
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.